Afficher la notice abrégée

A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGOUVERNEUR, Amandine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFERREIRA, Amandine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMORIVAL, Camille
dc.contributor.authorPAGEOT, Cecile
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDAUBECH-TOURNIER, Marie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.date.accessioned2021-05-10T13:57:11Z
dc.date.available2021-05-10T13:57:11Z
dc.date.issued2021-03-13
dc.identifier.issn1365-2125 (Electronic) 0306-5251 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/27234
dc.description.abstractEnAims: Antipsychotics and lithium are widely used in psychiatry, particularly in schizophrenia and bipolar disorders. Recently, some cases of somnambulism or sleep‐related eating disorder (SRED) have been reported in patients treated with these drugs. This study investigated the risk of reporting somnambulism or SRED associated with the use of antipsychotics and lithium. Methods: The World Health Organization pharmacovigilance database (VigiBase), comprising >18 million adverse events, was queried. All somnambulism or SRED reports related to antipsychotics or lithium were identified. The association between antipsychotics or lithium and somnambulism or SRED was computed using the proportional reporting ratio (PRR) and information component. Results: Among the 5784 cases reporting somnambulism or SRED, 508 suspected at least 1 antipsychotic or lithium. Most patients were aged 18–64 years (62.0%), and 37.0% were men. In most cases (77.6%), antipsychotic or lithium were the only drug class involved, and 53.3% of cases suspected quetiapine. Somnambulism was reported in 88.6% of cases and SRED in 18.1%. A significant association was found for second‐generation antipsychotics (PRR 3.44, 95% confidence interval 3.13) and lithium (PRR 2.03, [1.22; 3.37]), but not for first‐generation antipsychotics (PRR 0.99, [0.68; 1.44]). Conclusions: We found a significant signal of somnambulism or SRED related to second‐generation antipsychotics and lithium. While case reports mentioned mostly quetiapine and olanzapine, almost all second‐generation antipsychotics were associated with somnambulism or SRED.
dc.language.isoENen_US
dc.subject.enAntipsychotics
dc.subject.enDrug safety
dc.subject.enLithium
dc.subject.enPharmacovigilance
dc.subject.enSomnambulism
dc.title.enA safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/bcp.14818en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33713370en_US
bordeaux.journalBritish Journal of Clinical Pharmacologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03223031
hal.version1
hal.date.transferred2021-05-10T13:57:16Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2021-03-13&rft.eissn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.issn=1365-2125%20(Electronic)%200306-5251%20(Linking)&rft.au=GOUVERNEUR,%20Amandine&FERREIRA,%20Amandine&MORIVAL,%20Camille&PAGEOT,%20Cecile&DAUBECH-TOURNIER,%20Marie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée